Latest Breaking News On - Komal jhaveri - Page 1 : comparemela.com

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Komal jhaveriJames cayneEndocrine therapy research programMemorial sloan kettering cancer centerEarly drug development serviceJames cayne chairJunior faculty

ADCs for Breast Cancer: Clear Benefits, Manageable Risks

ADCs are rapidly changing the treatment landscape for patients with metastatic breast cancer, with the agents demonstrating improved efficacy and manageable risks.

Memorial sloan kettering cancer centerNew yorkUnited statesSoult ukpyolsiSouth koreaRepublic of koreaBae kimGiuseppe curiglianoKomal jhaveriEuropean society for medical oncologyUniversity of california san franciscoUniversity of milanUniversity of ulsan college medicineEuropean societyMedical oncologyBreast cancer

Dato-DXd May Be Better Tolerated Than Chemo in HR+/HER2– Breast Cancer

Dato-DXd May Be Better Tolerated Than Chemo in HR+/HER2– Breast Cancer
curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkJames cayneKomal jhaveriEndocrine therapy research programEuropean society for medical oncologyEarly drug development serviceAmerican cancer societyBreast cancer annual congressMedical oncologyBreast cancer annualJames cayne chairJunior facultyMemorial sloan kettering cancer center

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

James cayneKomal jhaveriEarly drug development serviceEndocrine therapy research programBreast cancer congressCancer congressJames cayne chairJunior facultyMemorial sloan kettering cancer center

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

James cayneKomal jhaveriMemorial sloan kettering cancer centerEarly drug development serviceEndocrine therapy research programJames cayne chairJunior facultyElaine 3Elaine 1Elaine 2Esr1 mutantEr her2 negative breast cancer